Meeting Archives
Chemotherapy Foundation Symposium XXIV
November 8-11, 2006
Marriott Marquis Hotel , New York , NY
Innovative Cancer Therapy for Tomorrow
Breast Cancer
Moderators: Seymour Cohen, Michael Goldsmith, George Raptis
| Joanne L. Blum, M.D. | Update On The Role Of Anti-Metabolites In Breast Cancer | View Presentation |
| Larry Norton, M.D. | Replacing Empiricism With Kinetic Modeling In Scheduling Therapy: Capecitabine | View Presentation |
| Edith A. Perez, M.D. | Anti-Her2 Adjuvant Therapy: New Data | View Presentation |
| Clifford A. Hudis, M.D. | Anti-Her2 Therapy: Beyond Trastuzumab | View Presentation |
| Norman Wolmark, M.D. | Ezra M. Greenspan Memorial Lecture New Strategies In Breast Cancer: The NSABP Clinical Trials | View Presentation |
| Gerald A. Soff, M.D. | The Role Of Tissue Factor Isoforms On Growth Of Cancer | View Presentation |
| Daniel F. Hayes, M.D. | Predictive And Prognostic Tests In Early Breast Cancer: Multigene Analysis | View Presentation |
| Eric P. Winer, M.D. | Genomics: Clinical Trials In Early Breast Cancer | View Presentation |
| Maura N. Dickler, M.D. | Antiangiogenic Therapy In Breast Cancer | View Presentation |
| Howard A. Burris, M.D. | Vinflunine In Breast Cancer | View Presentation |
| William J. Gradishar, M.D. | Ixabepilone In Locally Advanced & Metastatic Breast Cancer | View Presentation |
| Neelima Denduluri, M.D. | Inflammatory Breast Cancer: Antiangiogenic Therapy | View Presentation |
| Harold J. Burstein, M.D. | Optimizing Adjuvant Endocrine Therapy In Postmenopausal Early-Stage Breast Cancer | View Presentation |
| Rowan T. Chlebowski, M.D. | Trials Of Dietary Fat Intake And Breast Cancer Risk And Outcome | View Presentation |
| Dennis J. Slamon, M.D. | Cardiotoxicity In Adjuvant Treatment Of Breast Cancer | View Presentation |
| Craig Bunnell, M.D | Vinorelbine And Capecitabine In Metastatic Breast Cancer | View Presentation |
Diverse Therapeutic Strategies
| Judah Folkman, M.D. | Inhibitors In The Clinic: How To Use And Not Use Them | View Presentation |
| Charles L. Sawyers, M.D. | Kinase Inhibitors: Lessons From Chronic Myelogenous Leukema (CML) C | View Presentation |
| Mark Socinski, M.D. | Matuzumab: A New EGFR Inhibitor | View Presentation |
| Michael S. Gordon, M.D. | EM-1421: A New Anti-Cancer Agent | View Presentation |
| Michael Glantz, M.D. | Neurological Complications Of Non-Nervous System Cancers | View Presentation |
| John Glaspy, M.D. | Synchronization Of Erythropoietic Stimulating Protein Therapy With Chemotherapy | View Presentation |
| Allan Lipton, M.D. | AMS 162 (Denosumab) Phase I/II Trial In Bone Metastases | View Presentation |
| Richard A. Bender, M.D. | Carcinoma Of Unknown Primary: A Genomic Perspective | View Presentation |
| Howard A. Burris, M.D | Eniluracil And Oral 5 Fu | View Presentation |
| Frank Giles, M.D. | A Novel Aurora, BCR-ABL & JAK 2 Inhibitor (MK-0457) in CML, ALL, AML | View Presentation |
GI Cancers
Moderators: Howard S. Hochster, Steven Itzkowitz
| Edward Chu, M.D. | Update On The Role Of Oral Chemotherapy In Colorectal Cancer | View Presentation |
| Jordan D. Berlin, M.D. | Evolving Role Of Targeted Therapies In Metastatic Colorectal Cancer: Current Approaches | View Presentation |
| Axel Grothey, M.D. | Future Directions | View Presentation |
| Jaffer A. Ajani, M.D. | Future Development Of Docetaxel For Upper GI Cancers | View Presentation |
| Roger J. Waltzman, M.D. | Postoperative Chemoradiation In Resectable Gastric Cancer | View Presentation |
| David H. Ilson, M.D. | Esophagogastric Cancer: Advances In Treatment | View Presentation |
| Robert L. Fine, M.D. | Novel Lab-Based Treatments For Pancreatic Cancer | View Presentation |
| Robert A. Wolff, M.D. | Gemcitabine/Oxaliplatin Combinations In Locally Advanced Pancreatic Cancer | View Presentation |
| Robert G. Maki, M.D. | New Kinase-Targeted Agents For GIST | View Presentation |
| Steven H. Itzkowitz, M.D. | Colon Cancer Screening: New Methods | View Presentation |
| Howard S. Hochster, M.D. | Novel Agents In Colorectal Cancer | View Presentation |
| Howard A. Burris, M.D. | A Monoclonal Antibody (RAV 12) In Colon & Pancreatic Cancer | View Presentation |
| Nancy E. Kemeny, M.D. | Is There A Role For Hepatic Arterial Therapy In Colon Cancer After Liver Resection? | View Presentation |
| James C. Yao, M.D. | RAD001 & Depot Octreotide In Advanced Low/Intermediate Grade Neuroendocrine Carcinoma | View Presentation |
| Chandra P. Belani, M.D. | SAHA In Combination With Chemotherapy For NSCLC | View Presentation |
| Paulo M. Hoff, M.D. | Metastatic Colorectal Cancer: Is There One Standard Of Care? | View Presentation |
| Heinz-Josef Lenz, M.D. | UGT101: Predictor Of Toxicity And Efficacy Of CPT 11 | View Presentation |
| Michael A. Choti, M.D. | Biomarkers In Metastatic Colorectal Cancer | View Presentation |
GU Cancers
Moderators: Howard S. Hochster, Steven Itzkowitz
| William A. See, M.D. | Update On The Early Prostate Cancer (EPC) Trial | View Presentation |
| Noah M. Hahn, M.D. | Novel Chemotherapy Clinical Trials For Prostate Cancer | View Presentation |
| Daniel P. Petrylak, M.D. | Sipuleucel-T In Advanced Prostate Cancer | View Presentation |
| Kim N. Chi, M.D. | DN-101: An Oral Agent With Docetaxel | View Presentation |
| Oliver Sartor, M.D. | Novel Therapies For Hormone-Refractory Prostate Cancer: Oral Platinum Approaches | View Presentation |
Gynecological Cancers
Moderators: Carmel Cohen, Franco M. Muggia
| Deborah K. Armstrong, M.D. | Preferred Agents In Recurrent Ovarian Cancer | View Presentation |
| Franco M. Muggia, M.D. | Intraperitoneal Therapy: Pharmacology Prevails | View Presentation |
| Tamar Safra, M.D. | Weekly Paclitaxel/Carboplatin As Primary Treatment In Advanced Epithelial Ovarian Cancer | View Presentation |
| Michael A. Bookman, M.D. | Primary Therapy Of Advanced Ovarian Carcinoma | View Presentation |
| Stephanie V. Blank, M.D. | Front-Line Treatment In Ovarian, Tubal Or Primary Peritoneal Carcinoma: Erlotinib/Carboplatin/Paclitaxel | View Presentation |
| Jose M. del Campo, M.D. | Trabectedin (Yondelis) With Two Different Schedules In Platinum Sensitive Advanced Second And Third Line Ovarian Cancer | View Presentation |
| J. Tate T. Thigpen, M.D. | Potential Role Of Epothilones In Ovarian Carcinoma | View Presentation |
| Mark H. Einstein, M.D. | HPV Vaccines For Cervical Neoplasia | View Presentation |
Head & Neck Cancer
| Marshall R. Posner, M.D. | Current Trials With Anti-EGFR Antibodies In Head And Neck Cancer | View Presentation |
Hematologic Malignancies
Moderators: George Atweh, Janice L. Gabrilove
| Hagop M. Kantarjian, M.D. | Update On Role Of Histone Deacetylase Inhibitors In AML & MDS | View Presentation |
| Francine M. Foss, M.D. | HDAC Inhibitors In CTCL | View Presentation |
| Steven T. Rosen, M.D. | Pilot Trial Of Alemtuzumab | View Presentation |
| Kanti R. Rai, M.D. | Oblimersen In CLL: Long-Term Followup On Minimal Residual Disease | View Presentation |
| Hagop M. Kantarjian, M.D. | New Tyrosine Kinase Inhibitors In CML | View Presentation |
| Hetty E. Carraway, M.D. | Do Histone Deacetylase Inhibitors Synergize Clinically With 5-Azacitidine In MDS And AML? | View Presentation |
| Azra Raza, M.D. | Azacytidine And Thalidomide In MDS And AML | View Presentation |
| Stefan Faderl, M.D. | Clofarabine In Adult AML | View Presentation |
| John P. Leonard, M.D. | Pixantrone: A Novel Chemotherapeutic Agent For NHL | View Presentation |
| Richard I. Fisher, M.D. | Treatment Of Aggressive NHL | View Presentation |
| Wen-Kai Weng, M.D. | Vaccine Therapy In NHL | View Presentation |
| David G. Maloney, M.D. | Indolent Follicular Lymphoma | View Presentation |
| Jean-Francois Rossi, M.D. | Rituximab & GM-CSF Activity In Low-Grade Lymphoma | View Presentation |
| Paul A. Hamlin, M.D. | Rituximab In Upfront DLBCL | View Presentation |
| Susan M. O'Brien, M.D. | Obataclax: A Small Molecule Pan BCL-2 Family Inhibitor With Activity In Hematologic Malignancies | View Presentation |
| Farhad Ravandi, M.D. | Pentostatin In Lymphoid Neoplasms | View Presentation |
| S. Vincent Rajkumar, M.D. | Emerging Options In Newly Diagnosed & Relapsed Myeloma | View Presentation |
| James R. Berenson, M.D. | Multicenter Study Of Melphalan/Arsenic Trioxide/Vitamin C In Relapsed Or Refractory Multiple Myeloma | View Presentation |
| Hagop M. Kantarjian, M.D. | Update Of Hypomethylation Strategies In Leukemia And MDS | View Presentation |
Lung Cancer
| Chandra P. Belani, M.D. | Nab-Paclitaxel (Abraxane) For NSCLC | View Presentation |
| John R. Eckardt, M.D. | One Vs Two Drugs In Second-Line NSCLC: Is There Ever A Cause For A Doublet? | View Presentation |
| Cory J. Langer, M.D. | Adjuvant Therapy In NSCLC: Exploring A New Frontier | View Presentation |
| Ronald B. Natale, M.D. | Lung Cancer In Never-Smoking Women | View Presentation |
| Mark Socinski, M.D. | Gender Specific Therapy: Xyotax Vs Paclitaxel In Women With NSCLC | View Presentation |
| F. Anthony Greco, M.D. | Albumin Bound Paclitaxel Wkly+Carboplatin: First-Line Therapy For Advanced NSCLC | View Presentation |
| Craig H. Reynolds, M.D. | Nab-Paclitaxel/Carboplatin/Bevacizumab In Advanced Non-Squamous NSCLC | View Presentation |
| Rebecca S. Heist, M.D. | VEGFR Tyrosine Kinase Inhibitors In NSCLC | View Presentation |
| Amir Onn, M.D. | ZD6474: Preclinical And Clinical Data | View Presentation |
| F. Anthony Greco, M.D. | VNP40101M (Cloretazine) In SCLC | View Presentation |
| Ronald B. Natale, M.D. | Vaccines: Clinical Data On Survival In NSCLC | View Presentation |
| Cory J. Langer, M.D. | Emerging Role Of Sorafenib In The Treatment Of NSCLC | View Presentation |
Melanoma
| Keith T. Flaherty, M.D. | Therapeutic Value Of Map Kinase Pathway Inhibition | View Presentation |
| Sanjiv S. Agarwala, M.D. | Oblimersin In Melanoma: Update | View Presentation |
Practice Issues
| Susan H. Parker, M.D. | Private Payer Dynamics In 2006 | View Presentation |
Renal Cell Cancer
| Robert J. Motzer, M.D. | Sunitinib-Targeted Therapy For Renal Cell Carcinoma | View Presentation |
| Ronald M. Bukowski, M.D. | Sorafenib: A Multifunctional Tyrosine Kinase Inhibitor - Role In Metastatic Renal Cell Carcinoma? | View Presentation |
Thyroid Cancer
| Samuel A. Wells, M.D. | Targeted Therapy For Thyroid Cancer | View Presentation |
